Protecting your workforce supply chain under new UK tax rules

From April 2026, new Joint and Several Liability (JSL) legislation will reshape how UK organisations manage their workforce supply chains. Any business engaging workers through umbrella companies will face increased exposure if PAYE and National Insurance (NI) are not handled correctly. Under these rules, HMRC will be able to recover unpaid tax from recruitment agencies and, depending on the supply chain structure, from end clients too.  

For life sciences organisations that rely on a mix of permanent teams, contingent workers and specialist contractors to maintain momentum in R&D, clinical development and manufacturing, these changes introduce new compliance pressures that you can’t afford to ignore. 

R&D Partners works with clients across the full drug development lifecycle and we understand how fragile project timelines can be. Workforce disruption caused by non-compliant payroll practices is a risk that now carries both operational and financial consequences. 

This guide outlines what the legislation means for your organisation and how you can strengthen your supply chain ahead of the changes. 

The growing compliance challenge in the umbrella market

The umbrella sector has faced increasing scrutiny in recent years. Between 2022 and 2023, more than 275,000 flexible workers were engaged through umbrella companies that did not meet required tax obligations. The issue escalated further in December 2024 when the High Court issued an interim order against Ducas Limited (Maxipay) following allegations of £171 million in unpaid employer NI.

For life sciences organisations, this means:

• Operational functions dependent on flexible resource will be more exposed
• Project delivery timelines may be affected
• Reputational risk increases when third party payroll failures emerge
• Financial liability may extend further up the supply chain under JSL

With these changes approaching in April 2026, payroll integrity is becoming as important as assessing skills or experience.

Understanding Joint and Several Liability (JSL)

JSL gives HMRC new powers to recover unpaid PAYE and NI from any party involved in the engagement chain if an umbrella company fails to operate PAYE correctly. This can include: 

• The recruitment partner
• Third party intermediaries
• Potentially the end client, depending on the structure of the supply chain 

This applies even when the organisation did not choose the umbrella company.

What this means for growing organisations

If you are increasing headcount, expanding specialist teams or scaling project capacity, you may still be held responsible for: 

• Unpaid PAYE and NI
• Associated penalties and interest
• External scrutiny of your supply chain
• Reputational impact linked to non-compliant providers

In a sector where quality, documentation and regulatory oversight define success, JSL introduces a new layer of governance that must be built into workforce planning. 

Key risks to life sciences organisations

1. Financial liability under JSL
   Organisations can now be held responsible for unpaid PAYE or NI created by a non-compliant umbrella provider.
2. Compliance and governance exposure
   The Criminal Finances Act places responsibility on businesses to prevent tax evasion within the supply chain.
3. Operational disruption
   Non-compliant payroll increases the likelihood of assignment dropouts, which can delay critical project milestones.
4. Reputational risk
   Regulators, partners and investors expect robust governance across the full workforce model.

For organisations operating under strict regulatory standards, these risks require proactive management. 

Why contractor risk impacts organisational growth

Non-compliant umbrella arrangements continue to create significant exposure for contractors. When workers are placed into payroll models that do not meet HMRC requirements, they can later face unexpected tax demands, penalties or retrospective assessments. The uncertainty and financial pressure this creates often leads to reduced focus, disengagement or, in some cases, contractors stepping away from assignments while they seek advice. 

For life sciences organisations, these issues go beyond the immediate impact on individual workers. Project teams rely on continuity, specialist knowledge and predictable capacity to maintain progress across R&D, clinical activity and manufacturing. Any disruption to key personnel can slow development programmes, delay regulatory submissions, affect production schedules or limit commercial and medical operations. 

As organisations prepare for growth, maintaining a stable contractor population is becoming a strategic priority. Workforce disruption caused by payroll non-compliance now carries operational, governance and financial consequences that can hinder momentum at critical stages of development.  

How R&D Partners supports compliance under JSL

R&D Partners provides specialist workforce solutions to life sciences organisations and works closely with clients to minimise exposure across their supply chains.

1. A fully vetted panel of umbrella partners

We work only with umbrella companies that meet recognised industry standards, including those holding FCSA accreditation and SafeRec certification for real time payroll auditing.

2. Clear governance and contractual protection

We ensure client agreements include defined responsibilities, audit rights and oversight provisions, helping organisations strengthen compliance frameworks before the legislation takes effect. 

3. Ongoing monitoring across the supply chain

Our team conducts regular reviews of umbrella providers to ensure compliance remains active and consistent. Accreditation changes, risk indicators or operational concerns are identified early and escalated. 

4. Reduced administrative burden for internal teams

Managing umbrella compliance can consume valuable internal capacity. R&D Partners removes this pressure by maintaining up to date due diligence, monitoring and documentation. 

What organisations should do now

To prepare for the changes ahead, we recommend that life sciences organisations:

• Map their full workforce supply chain to establish where umbrella companies are being used 
• Work only with recruiters and umbrellas that provide full PAYE transparency 
• Review agreements to ensure accountability and audit rights are in place 
• Educate HR, compliance and procurement teams about JSL obligations 
• Conduct recurring checks on payroll and financial processes

R&D Partners can support you with all of these steps, whether that’s helping you assess your current exposure, reviewing your supplier setup or advising on the processes and controls you need in place. These actions will help ensure you are protected ahead of April 2026 and aligned with HMRC expectations. 

Build a compliant workforce strategy with R&D Partners

As the UK moves toward stricter oversight of umbrella company practices, organisations must act now to reinforce supply chain compliance. R&D Partners provides the governance, expertise and monitoring required to support uninterrupted operations and minimise risk as your organisation grows. 

Want to understand what this legislation means for your workforce? Get in touch with our team today.